Most people arriving at this question are comparing the wrong things. NMN is not an alternative to NAD⁺ — it is one of the two common ways of getting more of it. So is NR. Both are precursors: molecules your body converts into NAD⁺. Asking “NMN or NAD⁺” is a bit like asking whether you want flour or bread.
The question worth asking is NR versus NMN, and then whether either is better than paying several times more for an injection of NAD⁺ itself.
What each one has been shown to do
Nicotinamide riboside (NR) is the more heavily studied of the two. It raised the NAD⁺ metabolome in aged human skeletal muscle[1], raised NAD⁺ in plasma extracellular vesicles in a randomized trial [2], and has been through dedicated safety work showing no difference in adverse events versus placebo[3] — a trial authored by the ingredient’s manufacturer, which is worth knowing.
Nicotinamide mononucleotide (NMN) has a smaller but real body of trials. In a randomized, double-blind, placebo-controlled trial of 80 healthy middle-aged adults (n = 80), blood NAD rose significantly in every NMN group — 300, 600 and 900 mg daily — at day 30 and day 60 against both placebo and baseline (all p ≤ 0.001), and six-minute walking distance was significantly higher than placebo in all three dose groups (all p < 0.01) [4]. In postmenopausal women with prediabetes, NMN increased insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp, with no change on placebo [5].
So which is better?
On weight of published human evidence, NR — it has more trials behind it, and it is the ingredient most of the research people cite actually used. On breadth of measured outcomes, the NMN trials above are among the more interesting results in the field, because they measured something a person could notice rather than only a blood marker.
Neither has established the thing the category is sold on. Raising NAD⁺ is demonstrated for both. That raising it slows aging, restores energy or sharpens cognition in healthy people is not established in controlled human outcome trials, for NR, for NMN, or for any injectable or IV product.
One practical difference is regulatory rather than scientific: NMN’s status as a lawful dietary supplement ingredient in the United States is unresolved, which can affect whether you can buy it rather than whether it works.
Precursor or injection?
This is where the comparison gets genuinely lopsided, and it is the reason we keep returning to it. Everything cited above comes from trials of oral precursors. The injections, drips and sprays sold as NAD⁺ therapy have no controlled outcome trials supporting the benefits they advertise, and no comparable safety data either. They also cost several times more.
If you want the option with the most evidence at the lowest price, it is an oral precursor — a category we earn nothing from, and say so on the page where we recommend it.